Simultaneous Removal of Leached Protein A, Aggregates, DNA, and Endotoxin from mAbs


The recent dramatic increase in the number of monoclonal antibodies (mAbs) entering biopharmaceutical product pipelines has created the need for highly efficient purification process development. The concept of platform purification has evolved in response to that need. Platforms are semi-generic multistep procedures that are applicable to most antibodies and result in good purification performance with minimal development. A primary goal of this approach is to accelerate product entry into clinical trials and identify the most qualified candidates as early as possible.
Read more